CRISPRMED25 Launches with Afternoon Virtual Session to Be Followed by Four Days of In-Person Sessions

The first day of the 2^nd Annual CRISPR* Medicine 2025 Conference (CRISPRMED25) April 7-11 in Copenhagen, Denmark, was an afternoon virtual session featuring oral presentations by five outstanding scientists/physicians/executives and multiple stimulating poster sessions. This carefully curated event brings together 400+ researchers, scientists, and industry professionals from around the world (129 companies and institutions) to explore cutting-edge developments in the field.

Building on the success of CRISPRMED24’s virtual event, this year’s virtual program shone the spotlight on significant clinical advances and emerging therapeutic applications, including innovative approaches to treating a range of cancers and some of the rarest genetic diseases. The accessible online platform offered attendees a unique opportunity to gain insights from leading experts while connecting with peers across the global CRISPR Medicine community.

Registrants for the virtual event will have access on-demand to all the presentations from the in-person conference shortly after the final conference day. The April 8-11 sessions of CRISPRMED25 will be in-person events. The April 7 virtual session speakers and their presentations/abstracts are described below. The talks were followed by a virtual session for eleven poster presentations which are described in a separate BioQuick News story. [Editor’s Note: Most of the text below is drawn from presenter bios and abstracts posted prior to the virtual session.]

VIRTUAL ORAL PRESENTATION SESSION
(Moderated by Karen O’Hanlon Cohrt, Editor-in-Chief, CRISPR Medicine News)

“Fetal Gene Therapy in a Mouse Model of Krabbe Disease Using Virus-Like Particles”
–Asma Naseem, PhD, UCL Great Ormand Street Institute of Child Health (UK)

Asma Naseem, PhD, is a Senior Research Fellow in the Infection, Immunity, and Inflammation Department at University College London’s Great Ormond Street Institute of Child Health. Her research focuses on advancing innovative gene therapy and genome-editing technologies to develop transformative treatments for rare diseases, particularly primary immunodeficiencies and neurodegenerative lysosomal storage disorders. By leveraging cutting-edge gene editing and delivery tools, she aims to pave the way for novel therapies that significantly improve patient outcomes and provide hope for conditions with limited or no existing treatment options.

Continue reading the virtual presentation roundup at BioQuick News here.